drugset / Trial / NCT02445586
Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 4, single-arm, open-label, multicenter study to assess the safety and efficacy of pertuzumab in combination with trastuzumab and docetaxel for the treatment of participants with human epidermal growth factor receptor 2 (HER2)-positive advanced (locally recurrent, unresectable, or metastatic) breast cancer.
Timeline
- Start
- 2015-08-17
- Primary completion
- 2018-09-26
- Completion
- 2018-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | Intravenous |
| Background | Docetaxel | Small molecule | — | — |
| Background | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |